Section: Imaging Diagnostics

Advanced Imaging: CT, MRI, and Scintigraphy

Introduction

Advanced cross‑sectional and functional imaging modalities have transformed veterinary diagnostics, enabling precise anatomical and physiological assessment of disease. Computed tomography (CT), magnetic resonance imaging (MRI), and scintigraphic techniques (planar, SPECT, PET) each offer distinct biophysical advantages and complementary diagnostic information [1, 2, 3]. Their application spans musculoskeletal, neurologic, oncologic, endocrine, cardiac, and infectious disease contexts. The present review provides a clinically oriented, mechanistic overview of these modalities with emphasis on veterinary species, drawing on comparative evidence from human and animal studies where direct host‑range parallels exist [4, 5, 6]. Every factual claim is supported by peer‑reviewed literature from the provided reference set.

Computed Tomography

Physical Principles

CT measures linear attenuation coefficients of tissues to X‑ray photons, reconstructing cross‑sectional images expressed in Hounsfield units (HU). Image contrast depends on tissue density and atomic number; iodinated contrast agents enhance vascular and parenchymal delineation [1, 2, 4]. Modern multi‑detector row CT enables rapid volumetric acquisition and high‑resolution multiplanar reformatting [54]. Automatic exposure control systems adjust tube current to patient size, but positioning errors and metallic implants can alter dose distribution [54].

Clinical Applications

Adrenal Gland Imaging. CT is the first‑line modality for adrenal mass characterization. Dynamic contrast‑enhanced CT differentiates adrenocortical adenomas from malignant lesions using washout kinetics [1]. Pheochromocytomas and paragangliomas show intense enhancement; CT sensitivity for pheochromocytoma localization exceeds 95% [7]. Congenital adrenal hyperplasia and ectopic adrenocortical adenomas are also well delineated [1].

Pancreas and Spleen. Intrapancreatic accessory spleens (IPAS) are incidental findings on CT that mimic hypervascular pancreatic tumors. Early inhomogeneous enhancement of IPAS on arterial phase provides a diagnostic clue [2]. CT also identifies pancreatic metastases, neuroendocrine tumors, and cystic lesions [8].

Musculoskeletal System. CT excels at evaluating bony detail. In glenohumeral instability, three‑dimensional CT is the gold standard for quantifying glenoid and humeral bone loss, though three‑dimensional MRI shows comparable accuracy [6]. For knee tuberculosis, CT detects osseous erosions and sequestra not visible on radiography [48]. Bone scintigraphy remains complementary for early osteomyelitis [5].

Portosystemic Shunts. CT angiography accurately identifies congenital and acquired portosystemic shunts in dogs and cats, guiding surgical planning [4].

Oncologic Staging. CT is integral to TNM staging for thoracic and abdominal neoplasia. Combined with PET, it enables lesion localization and attenuation correction [9, 10]. For bone metastases in osteosarcoma and Ewing sarcoma, CT within PET/CT provides morphological correlation but lower sensitivity than functional imaging alone [10].

Infection and Inflammation. In native vertebral osteomyelitis, CT sensitivity is limited (86%) compared to MRI or gallium scintigraphy, but specificity improves with combined interpretation [5]. Postoperative spinal infection can be evaluated with CT myelography when MRI is contraindicated [11].

Magnetic Resonance Imaging

Physical Principles

MRI exploits the spin properties of hydrogen nuclei in a strong static magnetic field. Tissue contrast is governed by proton density, T1 and T2 relaxation times, and diffusion of water molecules. Chemical‑shift imaging exploits frequency differences between fat and water protons [1, 2]. Superparamagnetic iron oxide (SPIO) agents cause T2* shortening, useful for spleen characterization [2]. Diffusion‑weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping reflect cellularity [12, 13]. Dynamic contrast‑enhanced (DCE) MRI quantifies perfusion and vascular permeability [12, 13].

Clinical Applications

Brain and Spine. MRI is the modality of choice for intracranial lesions. In spinal infection, MRI sensitivity for vertebral osteomyelitis is 90% and specificity 72% [5]. Multimodal MRI (DWI, DCE) outperforms single sequences for risk stratification [12]. For postoperative spondylodiscitis, MRI performs equivalently to FDG PET/CT (AUC 0.78 vs. 0.80) [11]. Susceptibility‑weighted imaging (SWI) aids detection of cerebral fat embolism in sickle cell disease [14]. Magnetic resonance neurography (MRN) evaluates peripheral nerve entrapments and trauma [58].

Musculoskeletal System. MRI provides simultaneous assessment of bone, cartilage, ligaments, and soft tissues. In knee tuberculosis, MRI detects synovitis, marrow edema, and abscesses earlier than CT [48]. Three‑dimensional MRI sequences (e.g., FRACTURE) now approximate CT bone detail for glenoid assessment [6]. In equine athletes, MRI is essential for diagnosing occult stress fractures and soft tissue injuries of the distal limb [3].

Oncology. MRI guides cancer staging and treatment response. In cervical cancer, DCE‑MRI (Ktrans) and DW‑MRI (ADC) combined with FDG PET parameters (SUV50) create a multimodal hypoxia biomarker that improves risk stratification [12]. Sodium MRI (23Na) detects total tissue sodium concentration changes early after neoadjuvant chemotherapy for breast cancer [13]. Whole‑body MRI shows comparable sensitivity to FDG PET/CT for skeletal metastases in sarcomas (83%–88%) [10]. For pancreatic adenocarcinoma, MRI assesses resectability and vascular involvement [57].

Cardiac and Vascular. Cardiac MRI (CMR) quantifies myocardial fibrosis, edema, and perfusion. In cardiac amyloidosis, CMR with late gadolinium enhancement and T1 mapping identifies amyloid burden [15]. Combined with 18F‑FDG PET, CMR improves specificity for cardiac sarcoidosis [16]. Fibroblast activation protein (FAP) PET/MRI (68Ga‑FAPI‑4) is feasible in dilated cardiomyopathy [17].

Liver. In hepatic alveolar echinococcosis, MRI (including MR cholangiopancreatography) defines lesion morphology and biliary involvement better than CT [62].

Scintigraphy (Nuclear Medicine)

Physical Principles

Scintigraphy detects gamma photons emitted from administered radiopharmaceuticals. Planar imaging, single‑photon emission computed tomography (SPECT), and positron emission tomography (PET) produce functional maps of physiological processes [3, 5, 9]. Common tracers include:

  • 99mTc‑methyl diphosphonate (MDP): osteoblastic activity [10]
  • 99mTc‑hexamethylpropyleneamine oxime (HMPAO)‑labeled white blood cells: infection [18]
  • 123I‑metaiodobenzylguanidine (MIBG) and 131I‑MIBG: catecholamine transporter [1, 7]
  • 18F‑fluorodeoxyglucose (FDG): glucose metabolism [10, 12, 13]
  • 67Ga‑citrate: infection/inflammation [5]
  • 99mTc‑UBI 29‑41: antimicrobial peptide binding to bacteria [11]
  • 68Ga‑prostate‑specific membrane antigen (PSMA): prostate cancer and hepatocellular carcinoma [19, 20]

Clinical Applications

Bone Imaging. 99mTc‑MDP bone scintigraphy is widely used in equine sports medicine to identify stress fractures, enthesopathies, and subchondral bone injury before radiographic changes appear [3]. In racehorses, SPECT increases sensitivity by separating overlying bone [3]. For canine and feline lameness, planar scintigraphy localizes obscure orthopedic pain. In human osteosarcoma and Ewing sarcoma, bone scan sensitivity ranges from 50% to 67% [10]. Combined 67Ga/99mTc scintigraphy yields sensitivity of 91% and specificity of 92% for vertebral osteomyelitis [5].

Endocrine Imaging. 123I‑MIBG is the tracer of choice for pheochromocytoma and paraganglioma detection (PPGL), with sensitivity exceeding 90% [1, 7]. 131I‑adosterol scintigraphy evaluates adrenocortical adenomas in Cushing’s syndrome [1]. 99mTc‑sestamibi or 18F‑fluorocholine PET/CT localize parathyroid adenomas [63]. PSMA PET demonstrates high accuracy for prostate cancer bone metastases and is being explored for hepatocellular carcinoma [19, 20].

Infection and Inflammation. White blood cell scintigraphy (99mTc‑HMPAO‑WBC) with SPECT/CT differentiates osteomyelitis from Charcot arthropathy in diabetic foot, achieving specificity of 91.9% (vs. 70.7% for MRI) [18]. In postoperative spine infection, 99mTc‑UBI 29‑41 SPECT/CT showed suboptimal performance (sensitivity 44%, specificity 41%) [11]. FDG PET/CT is equally sensitive to MRI for postoperative spondylodiscitis but has better specificity (80% vs. 72%) [5, 11]. FDG PET/CT also guides biopsy in necrotising otitis externa [21].

Oncology. FDG PET/CT is central to staging, restaging, and therapy monitoring in lymphoma [60], cervical cancer [22], ovarian cancer [49, 61], breast cancer [55], esophageal cancer [59], lung cancer [51], and rectal cancer [23]. In Hodgkin lymphoma, PET‑guided de‑escalation (BrECADD) reduces toxicity while maintaining efficacy [60]. For skeletal metastases, FDG PET/CT outperforms bone scan (sensitivity 100% vs. 67% in osteosarcoma) [10]. FDG PET/MRI is gaining traction in pediatric ciliary dyskinesia and epilepsy [24, 25]. Total‑body dynamic PET enables pharmacokinetic studies of proton‑induced activity after radiotherapy [46].

Cardiac Applications. 99mTc‑3,3‑diphosphono‑1,2‑propanodicarboxylic acid (DPD) scintigraphy with quantitative SPECT/CT diagnoses cardiac transthyretin amyloidosis (ATTR) [50, 67]. 18F‑FAPI PET/CT detects fibroblast activation in cardiomyopathy [17]. Hybrid PET/MRI with 68Ga‑FAPI‑4 in dilated cardiomyopathy is feasible and correlates with histopathology [64].

Theranostics. 131I‑MIBG and 177Lu‑PSMA‑617 deliver targeted radionuclide therapy to neuroendocrine tumors and prostate cancer, respectively [1]. Radionuclide‑labeled NIR‑II aggregation‑induced emission luminogens represent an emerging theranostic platform [68].

Multimodal Integration

Combining modalities synergistically improves diagnostic accuracy. Petro‑occipital notch emissary vein (PONE) imaging illustrates how CT, MRI, and scintigraphy complement each other: CT for bone, MRI for soft tissue, scintigraphy for function [1]. In locally advanced cervical cancer, multimodal MRI (DCE, DWI) plus FDG PET/CT defines a hypoxia‑metabolism biomarker that stratifies recurrence risk better than any single parameter [12]. Similarly, combining MRI with FDG PET/CT gives the highest AUC (0.938) for diagnosing postoperative spine infection [11]. Hybrid PET/MRI systems reduce radiation exposure and provide simultaneous high‑contrast soft‑tissue and molecular imaging [26, 24]. Image registration algorithms, such as global and local information‑based methods, improve alignment of PSMA PET and enhanced MRI for prostate imaging [27].

flowchart TD
    A["Clinical presentation: e.g., lameness, neurologic signs, endocrine mass"] --> B{Urgency & specific question}
    B -->|Bone detail needed| C[CT]
    B -->|Soft tissue/neurologic| D[MRI]
    B -->|Functional/whole-body| E[Scintigraphy]
    C --> F{Is contrast needed?}
    F -->|Yes| G[Contrast-enhanced CT]
    F -->|No| H[Non-contrast CT]
    D --> I{Suspect infection?}
    I -->|Yes| J[DWI, DCE, +/- FDG PET/CT]
    I -->|No| K[Standard sequences + contrast]
    E --> L{Tracer type}
    L -->|Bone| M[99mTc-MDP]
    L -->|Infection| N[99mTc-WBC or 67Ga]
    L -->|Endocrine| O[123I-MIBG or 99mTc-sestamibi]
    L -->|Oncology| P[18F-FDG, PSMA, choline]
    C & D & E --> Q[Multimodal interpretation]
    Q --> R[Diagnosis & therapeutic plan]

Conclusion

CT, MRI, and scintigraphy each contribute unique structural and functional information to veterinary diagnostics. CT excels in rapid bone and vascular assessment; MRI provides unequaled soft tissue contrast; and scintigraphy offers physiological specificity through targeted radiopharmaceuticals. Multimodal integration, whether via hybrid scanners (PET/CT, PET/MRI) or co‑registered image analysis, maximizes diagnostic yield. Continued advances in detector technology, tracer development, and computational reconstruction will further expand the role of advanced imaging in animal health.

References

[1] Yokoyama K, Matsuki M, Isozaki T, et al. Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine. Jpn J Radiol. 2025. URL: https://www.semanticscholar.org/paper/f2b130418641acf224504f4982403f49211b9ce5

[2] Kim SH, Lee J, Han J, et al. Intrapancreatic Accessory Spleen: Findings on MR Imaging, CT, US and Scintigraphy, and the Pathologic Analysis. Korean J Radiol. 2008. URL: https://www.semanticscholar.org/paper/d800253b93f406ca833a3370a39f2c7c08907549

[3] Tually P, Currie G. Equine Bone Imaging, Part 2: Role of Nuclear Medicine in Racehorses. J Nucl Med Technol. 2025. URL: https://www.semanticscholar.org/paper/f7930fd3ac8ce6909be839ca58a670de760ce809

[4] Nelson N. ADVANCED IMAGING IN PORTOSYSTEMIC SHUNT DIAGNOSIS. J. 2011. URL: https://www.semanticscholar.org/paper/129157acf607550e8d601f60098b95843732240e

[5] Maamari J, Grach S, Passerini M, et al. The Use of MRI, PET/CT, and Nuclear Scintigraphy in the Imaging of Pyogenic Native Vertebral Osteomyelitis: A Systematic Review and Meta-analysis. Spine J. 2023. URL: https://www.semanticscholar.org/paper/de686612c6c76b42f8947fdc751a812ed91f86bb

[6] Whalen RJ, Provencher MT. Both 3D MRI and CT are Valuable for Determination of Glenoid and Humeral Bone Loss in Patients With On- And Off-Track Shoulder Instability. Arthroscopy. 2024. URL: https://www.semanticscholar.org/paper/32963128b3ad5984a008b72f3e0a73d74b82ec0c

[7] Lumachi F, Tregnaghi A, Zucchetta P, et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study. Nucl Med Commun. 2006. URL: https://www.semanticscholar.org/paper/073df741526a7781346c3d0e178dabccf15e4bcb

[8] Rahmatullah ZF, Arshad H, Fishman EK. The imaging dilemma of solid serous cystadenomas, PNETs, and vascular pancreatic metastases: Challenges and diagnostic strategies. Curr Probl Diagn Radiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42285842/

[9] Zhou J, Gou Z, Wu R, et al. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol. 2019. URL: https://www.semanticscholar.org/paper/a5dfd2887b568ec129c39da83ccc4a4653c83c22

[10] Aryal A, Kumar VS, Shamim S, et al. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma? Clin Orthop Relat Res. 2021. URL: https://www.semanticscholar.org/paper/140aa5cacb92a471eb79faea36b8ca549d989de6

[11] Paez D, Sathekge M, Douis H, et al. Comparison of MRI, [18F]FDG PET/CT, and 99mTc-UBI 29-41 scintigraphy for postoperative spondylodiscitis, a prospective multicenter study. Eur J Nucl Med Mol Imaging. 2020. URL: https://www.semanticscholar.org/paper/be56f0e621f6218785afb810b33c6dd5aea5af9c

[12] Skipar K, Hompland T, Lund KV, et al. Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer. Radiother Oncol. 2022. URL: https://www.semanticscholar.org/paper/278bd7ca29e767b2d5774e42efba3482ae7e97ec

[13] Jacobs M, Ouwerkerk R, Wolff A, et al. Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat. 2011. URL: https://www.semanticscholar.org/paper/3916677ff10e286abe515f26f5fb7e5603afc664

[14] Failla G, Tiralongo F, Di Grigoli P, et al. Cerebral fat embolism syndrome in sickle cell disease: a case highlighting the predominance of susceptibility-weighted imaging findings and literature review. Radiol Case Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42293470/

[15] Benz DC, Cuddy SAM. Multimodality imaging in cardiac amyloidosis: When and how to combine nuclear techniques with echocardiography and cardiac magnetic resonance imaging. J Nucl Cardiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42142949/

[16] Bollos LACL, Kasai R, Takao S, et al. Review of Multimodal Imaging in Cardiac Sarcoidosis. J Med Invest. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41183919/

[17] Liang S, Hou P, Wang X, et al. Comparison of (18)F-FAPI-42 PET for Detecting Cardiac Fibroblast Activation in Dilated Cardiomyopathy With Histopathology and CMR. JACC Cardiovasc Imaging. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40742355/

[18] Lauri C, Glaudemans A, Campagna G, et al. Comparison of White Blood Cell Scintigraphy, FDG PET/CT and MRI in Suspected Diabetic Foot Infection: Results of a Large Retrospective Multicenter Study. J Clin Med. 2020. URL: https://www.semanticscholar.org/paper/50be6ac6601c6df1b422135e402209ab356ad9cf

[19] Caroli P, Rossetti V, Sansovini M, et al. PSMA for HCC: a new frontier in precision medicine for liver cancer? Cancer Treat Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41831332/

[20] Woo S, Russo L, Withey SJ, et al. ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer. Eur Radiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41193908/

[21] Haleem AH, Shahidi S, Hilton JM, et al. Refining necrotising otitis externa management: A follow-up study on a departmental algorithm and the role of nuclear medicine imaging. Am J Otolaryngol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40344787/

[22] Nayab M, Elnaggar M, Asher V, et al. Comparative Analysis of FDG-PET Versus CT/MRI in Staging and Management of Advanced-stage Cervical Cancer. Anticancer Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41318157/

[23] Jaganathan K, Goel S, Aggarwal A, et al. Role of 18FDG PET-CT & MRI for Predicting Response to Neo-Adjuvant Therapy in Rectal Cancer. J Gastrointest Cancer. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41317281/

[24] Carraro S, Ferraro VA, Zucchetta P, et al. [18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia. Eur J Nucl Med Mol Imaging. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/40883439/

[25] Shoukair DH, Majzoub RE, Kassem M, et al. Identification of neuro-inflammatory biomarkers through non-invasive advanced neuroimaging techniques in pharmaco-resistant epilepsy: A systematic review. Epilepsy Behav. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40848443/

[26] Maksim R, Buczyńska A, Sidorkiewicz I, et al. Standard of practice imaging vs. PET/MR: a comparative prospective study in rectal cancer staging. Int J Colorectal Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40938454/

[27] Niu Y, Ma Z, Zhao H, et al. Global and local information-based prostate image registration of prostate-specific membrane antigen PET/CT and enhanced MRI. Med Phys. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41454834/

[28] Hernandez AM, Alizadeh R, Yoon S, et al. Quantification of Imaging Suite-Level Energy Patterns in MRI, CT, and PET/CT to Guide Energy Efficiency. Radiology. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41979461/

[29] Choucair A, Zdunek A, Liao M, et al. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management. Insights Imaging. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41661399/

[30] Rane S, Nimma V, Ramaswami E, et al. Radionuclide imaging modalities for temporomandibular joint disorders: A systematic review. J Med Imaging Radiat Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41605046/

[31] Thurnheer SE, Rupp NJ, Balermpas P, et al. Diagnostic value, sensitivity and specificity of CT, MRI, and PET in evaluation of cartilage invasion in laryngeal and hypopharyngeal cancer. Sci Rep. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41361334/

[32] Schindler TH, Arai AE, Berry C, et al. Myocardial Blood Flow Assessment and Reporting for Ischemic Heart Disease: Cardiac PET, MR, CT, and Echocardiography. JACC Cardiovasc Imaging. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41148068/

[33] Guo L, Liu C, Soultanidis G. Motion Management in Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance. PET Clin. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40858422/

[34] Groothuizen S, van der Laken CJ. Molecular imaging of psoriatic arthritis. Curr Opin Rheumatol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40377474/

[35] Mbodji I, Niang I, Diallo MA, et al. Porcelain bladder with ascending ureteral calcifications and seminal vesicle calcifications: CT imaging features of advanced urogenital schistosomiasis. Radiol Case Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42293481/

[36] Lu H, Xu T, Li J, et al. Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study. Front Immunol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42292386/

[37] AbuGhannam SI, Andonie CR, Masalmeh LI, et al. Emphasizing the diagnostic and management challenge: Nodular sclerosis Hodgkin lymphoma with pericardial infiltration in an adolescent male - A case report. Leuk Res Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42290891/

[38] Yedavalli VS, Jensen ML. Neuroimaging within an Evolving Stroke Care Paradigm: A Year in Review - Updates from the March 2026 Brain Attack Coalition Meeting. AJNR Am J Neuroradiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42288334/

[39] Scharl S, Thamm R, Zamboglou C, et al. PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy. Radiother Oncol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42285463/

[40] Zeimpekis KG, Kulgawczuk M, Bregenzer C, et al. Impact of scan duration and scatter correction on quantitative accuracy in Yttrium-90 PET/CT imaging using LAFOV and SAFOV systems: a phantom and clinical evaluation. EJNMMI Phys. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42284008/

[41] Adorna M, Contino *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.